Accustem Sciences Inc. (ACUT)
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Accustem Sciences Inc.
Accustem Sciences Inc. (ACUT) dilution facts from SEC filings
Snapshot as of Jun 30, 2026, built from 2 SEC filings.
- Shelf registration
- None on file in the filings reviewed
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 1 warrant series recorded as outstanding
- Most recent offering
- None recorded in the filings reviewed
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.